Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Lung Cancers: An Update on Molecular Diagnostics and Therapy
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Lung Cancers: An Update on Molecular Diagnostics and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 May 2024 | Viewed by 2629

Special Issue Editor

Dr. Mariusz Chabowski

E-Mail Website
Guest Editor
Department of Surgical Clinical Science, Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland
Interests: colorectal cancers; thymoma; pulmonary medicine; malignant pleural effusion; video-assisted thoracic surgery; mesothelioma; transthoracic biopsy: bronchoscopy; cancer malnutrition; dietary intervention; cachexia; parenteral nutrition
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer is the most common cancer in Poland and world-wide. In 2018, over 2 million new lung cancer cases were diagnosed. Lung cancer is also the leading cause of cancer death. Despite efforts in finding new treatment options, the survival rate of patients with lung cancer remains low. New and innovative treatment paradigms are still being sought. The prognosis of lung cancer depends on the disease stage at diagnosis. The age and sex of the patient and the histologic type of the tumor are also relevant factors. In patients with advanced lung cancer, significant prognostic factors are performance status, fatigue, malnutrition, depression and treatment-related toxicity. Cancer cachexia is associated with a poor prognosis and high risk of death.

This Special Issue is open for submissions from any interested individuals. It is expected that contributions will include original research papers, authoritative and up-to-date reviews, and commentaries on the following topics and areas:

  • Novel drugs and therapeutic approaches for lung cancer;
  • Molecular mechanism for anti-lung cancer or cancer-preventive effects;
  • In vitro, in vivo and clinical studies related to lung cancer at the molecular level;
  • Usage of the therapeutic approaches in conjunction with cancer chemotherapeutic drugs;
  • Challenges and innovative approaches for anti-lung cancer drug development;
  • Novel approaches for lung cancer prevention and intervention;
  • Production of anti-lung cancer agents using biotechnology;
  • Pharmacokinetics and pharmacogenomic studies on anti-lung cancer drugs.

Dr. Mariusz Chabowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • cancer cachexia
  • prognosis
  • anti-lung cancer agents

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 1977 KiB  
Article
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
by Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M. S. Hashemi, Urska Janzic, Waleed Kian, Katja Mohorcic, Saara Mohammed, Maria Silvoniemi, Sacha I. Rothschild, Christian Schulz, Claas Wesseler, Alfredo Addeo, Karin Armster, Malinda Itchins, Marija Ivanović, Diego Kauffmann-Guerrero, Jussi Koivunen, Jonas Kuon, Nick Pavlakis, Berber Piet, Martin Sebastian, Janna-Lisa Velthaus-Rusik, Luciano Wannesson, Marcel Wiesweg, Robert Wurm, Corinna Albers-Leischner, Daniela E. Aust, Melanie Janning, Hannah Fabikan, Sylvia Herold, Anna Klimova, Sonja Loges, Yana Sharapova, Maret Schütz, Christoph Weinlinger, Arschang Valipour, Tobias Raphael Overbeck, Frank Griesinger, Marko Jakopovic, Maximilian J. Hochmair and Martin Wermkeadd Show full author list remove Hide full author list
Int. J. Mol. Sci. 2024, 25(7), 3992; https://doi.org/10.3390/ijms25073992 - 03 Apr 2024
Viewed by 1436
Abstract
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis [...] Read more.
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24–45). The response rate in treatment-naïve patients was 27% (95% CI, 8–58). The median progression-free and overall survival was 5 months (95% CI, 3.5–6.5) and 12 months (95% CI, 6.8–17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity. Full article
(This article belongs to the Special Issue Lung Cancers: An Update on Molecular Diagnostics and Therapy)
►▼ Show Figures

Figure 1

20 pages, 4762 KiB  
Article
Detailed Characterization of the Lung–Gut Microbiome Axis Reveals the Link between PD-L1 and the Microbiome in Non-Small-Cell Lung Cancer Patients
by Vytautas Ankudavicius, Darja Nikitina, Rokas Lukosevicius, Deimante Tilinde, Violeta Salteniene, Lina Poskiene, Skaidrius Miliauskas, Jurgita Skieceviciene, Marius Zemaitis and Juozas Kupcinskas
Int. J. Mol. Sci. 2024, 25(4), 2323; https://doi.org/10.3390/ijms25042323 - 15 Feb 2024
Viewed by 911
Abstract
Next-generation sequencing technologies have started a new era of respiratory tract research in recent years. Alterations in the respiratory microbiome between healthy and malignant conditions have been revealed. However, the composition of the microbiome varies among studies, even in similar medical conditions. Also, [...] Read more.
Next-generation sequencing technologies have started a new era of respiratory tract research in recent years. Alterations in the respiratory microbiome between healthy and malignant conditions have been revealed. However, the composition of the microbiome varies among studies, even in similar medical conditions. Also, there is a lack of complete knowledge about lung–gut microbiome interactions in lung cancer patients. The aim of this study was to explore the lung–gut axis in non-small-cell lung cancer (NSCLC) patients and the associations between lung–gut axis microbiota and clinical parameters (CRP, NLR, LPS, CD8, and PD-L1). Lung tissue and fecal samples were used for bacterial 16S rRNA sequencing. The results revealed, for the first time, that the bacterial richness in lung tumor tissue gradually decreased with an increase in the level of PD-L1 expression (p < 0.05). An analysis of β-diversity indicated a significant positive correlation between the genera Romboutsia and Alistipes in both the lung tumor biopsies and stool samples from NSCLC patients (p < 0.05). Survival analysis showed that NSCLC patients with higher bacterial richness in their stool samples had prolonged overall survival (HR: 2.06, 95% CI: 1.025–4.17, p = 0.0426). Full article
(This article belongs to the Special Issue Lung Cancers: An Update on Molecular Diagnostics and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop